Back to Prevention

Does Doxy-PEP Cause Antibiotic Resistance?

Does Doxy-PEP Cause Antibiotic Resistance?
Bareback Guide 15 January 2026

This is the main objection to widespread doxy-PEP and it deserves a serious answer rather than reassurance. Any repeated antibiotic exposure exerts selection pressure, and that pressure does not fall only on the organisms you are trying to prevent. It falls on everything living in and on you.

What is the concern with gonorrhoea?

Tetracycline resistance in Neisseria gonorrhoeae is already common, which is why doxy-PEP works less well against it than against chlamydia or syphilis. The worry is that repeated exposure could select further for resistant strains, making an infection that is already difficult to treat harder still. Gonorrhoea has already defeated penicillins, tetracyclines, ciprofloxacin and azithromycin in succession, and strains with reduced susceptibility to ceftriaxone have been identified in the UK.

What about organisms that are not the target?

This is arguably the larger question. Doxycycline reaches the gut, the skin and the throat, exerting pressure on bacteria that have nothing to do with sexual health. Studies have looked at effects on Staphylococcus aureus, where tetracycline resistance would have implications for treating skin and soft tissue infections, and at changes in gut flora. Signals have been mixed rather than absent, and this is an area under active surveillance.

What about chlamydia and syphilis?

Neither has shown significant tetracycline resistance despite decades of doxycycline use as treatment. That does not guarantee it will not emerge, and monitoring continues, but the organisms doxy-PEP works best against are also the ones where resistance has historically been least likely.

What has the trial data shown so far?

Follow-up from the main studies has looked for resistance emerging and has found some signals, particularly in staphylococcal isolates, without a clear picture of clinical consequence yet. The honest position is that the individual benefit is demonstrated and the population-level cost is not yet fully known. That asymmetry is why implementation has been cautious in the UK and elsewhere.

How is the risk being managed?

By targeting. Offering doxy-PEP to people with repeated bacterial infections concentrates the benefit where it is largest, and in that group it may reduce total antibiotic consumption, since preventing four infections avoids four treatment courses. Dose caps limit total exposure. Surveillance of resistance patterns continues nationally. And provision is being introduced through services that screen regularly rather than through open access.

Does this mean you should not use it?

Not necessarily. If you are eligible and having several bacterial infections a year, the calculation is likely to favour it for you personally, and it is a decision to make with a clinician rather than in the abstract. What it does mean is that using it more often than recommended, or obtaining it outside a service that monitors you, works against the reasoning that makes targeted provision defensible.

What can you do to reduce the downside?

Stay within the dosing limits your clinic sets. Keep screening every three months, so that infections which do occur are found and treated properly rather than partially suppressed. Complete the vaccination courses, particularly the meningococcal B vaccine for gonorrhoea where available, since vaccination reduces infections without antibiotic pressure.

Where this sits

Doxy-PEP is a genuine advance with a genuine cost, and the balance depends on who is taking it and how often. Treating the resistance concern as scaremongering is as unhelpful as treating it as a reason to reject the intervention outright.

Does it affect the bacteria that protect you?

Possibly. The throat carries harmless Neisseria species that share genetic material with gonorrhoea, and pressure on those organisms could in principle create a reservoir of resistance genes that gonorrhoea then acquires. This is a plausible mechanism rather than a demonstrated one, and it is among the things being watched.

How would we know if it were going wrong?

Through national surveillance of resistance patterns in gonorrhoea, chlamydia and syphilis, and through monitoring of organisms such as Staphylococcus aureus in people using doxy-PEP. The UK has good surveillance infrastructure for gonorrhoea in particular, which is one reason a cautious targeted rollout is workable rather than reckless.

Is this an argument against it?

It is an argument for using it where the benefit is real and for not extending it casually. Individual decisions and population policy are different questions here, and someone with repeated syphilis making a reasonable choice for themselves is not in tension with a national position that provision should stay targeted.